Advanced search
Publication Cover
Expert Review of Vaccines Volume 10, 2011 - Issue 10
Submit an article Journal homepage
458
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Proving the principle: dendritic cell-based vaccines in urogenital cancers

Andreas Draube Laboratory for Tumor and Transplantation Immunology, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Street 62, D-50924 Cologne, Germany
,
Nela Klein-González Laboratory for Tumor and Transplantation Immunology, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Street 62, D-50924 Cologne, Germany
&
Michael von Bergwelt-Baildon Department I of Internal Medicine, University Hospital of Cologne, Kerpener Street 62, D-50924 Cologne, Germany. [email protected]
Pages 1355-1357 | Published online: 09 Jan 2014

References

  • Rosenberg S, Yang J, Restifo N. Cancer immunotherapy: moving beyond current vaccines. Nat. Med.10(9), 909–915 (2004).
  • Finn OJ. Cancer immunology. N. Engl. J. Med.358(25), 2704–2715 (2008).
  • Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.363(5), 411–422 (2010).
  • Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med.363(8), 711–723 (2010).
  • Schlom J, Gulley JL, Arlen PM. Paradigm shifts in cancer vaccine therapy. Exp. Biol. Med. (Maywood)233(5), 522–534 (2008).
  • Brookman-May S, Burger M, Wieland WF, Rossler W, May M, Denzinger S. Vaccination therapy in renal cell carcinoma: current position and future options in metastatic and localized disease. Expert Rev. Vaccines10(6), 837–852 (2011).
  • Madan RA, Aragon-Ching JB, Gulley JL, Dahut WL. From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Rev. Vaccines10(6), 743–753 (2011).
  • Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines. J. Immunol.186(3), 1325–1331 (2011).
  • Draube A, Klein-González N, Mattheus S et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PloS One6(4), e18801 (2011).
  • Fong L, Brockstedt D, Benike C et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J. Immunol.167(12), 7150–7156 (2001).
  • Wierecky J, Muller MR, Wirths S et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res.66(11), 5910–5918 (2006).
  • Miller MJ, Hejazi AS, Wei SH, Cahalan MD, Parker I. T cell repertoire scanning is promoted by dynamic dendritic cell behavior and random T cell motility in the lymph node. Proc. Natl Acad. Sci USA101(4), 998–1003 (2004).
  • Butterfield LH, Ribas A, Dissette VB et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin. Cancer Res.9(3), 998–1008 (2003).
  • Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Ann. Rev. Immunol.24, 175–208 (2006).
  • Martin-Fontecha A, Sebastiani S, Hopken UE et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J. Exp. Med.198(4), 615–621 (2003).
  • Small EJ, Fratesi P, Reese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol.18(23), 3894–3903 (2000).
  • Hoos A, Parmiani G, Hege K et al. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother.30(1), 1–15 (2007).
  • Copier J, Dalgleish AG, Britten CM et al. Improving the efficacy of cancer immunotherapy. Eur. J. Cancer45(8), 1424–1431 (2009).
  • Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med.364(26), 2517–2526 (2011).
  • Wiesner M, Zentz C, Mayr C et al. Conditional immortalization of human B cells by CD40 ligation. PloS One3(1), e1464 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.